{
  "ptid_time": "116_S_4898_2014-08-19",
  "img_path": "/data/qiuhui/data/adni/images/116_S_4898/2014-08-19/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 43,287 mm³, 12.4% above the reference mean. With a Z-score of 0.30 (61.7th percentile), this represents normal volume ; hippocampal volume measures 5,619 mm³, 25.7% below the reference mean. With a Z-score of -2.50 (0.6th percentile), this represents significant atrophy; whole brain volume measures 1,100,000 mm³, 1.9% above the reference mean. With a Z-score of 0.25 (59.8th percentile), this represents normal volume ; entorhinal cortex volume measures 2,749 mm³, 33.0% below the reference mean. With a Z-score of -2.24 (1.3th percentile), this represents significant atrophy; fusiform gyrus volume measures 20,293 mm³, 7.7% above the reference mean. With a Z-score of 0.66 (74.5th percentile), this represents normal volume ; middle temporal gyrus volume measures 23,392 mm³, 9.6% above the reference mean. With a Z-score of 0.86 (80.6th percentile), this represents normal volume . ",
  "text_data": "Age is 77.2 years. Gender is Male. Education: 20 years. MMSE: 29.0. MoCA: 30.0. Logical Memory: 12.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.18 SUVR (normal ); Amyloid beta: 704.90 pg/mL (normal ); Total tau: 177.90 pg/mL (normal ); Phosphorylated tau: 17.44 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The data shows significant atrophy in the hippocampus (-2.50 Z-score) and entorhinal cortex (-2.24 Z-score), both key regions affected in Alzheimer's disease, despite normal cognitive scores (MMSE 29, MoCA 30) and normal CSF biomarkers (Aβ, T-tau, P-tau) and AV45 PET. This suggests possible preclinical Alzheimer's or early neurodegeneration without clinical symptoms.  \n\n**Diagnosis:** **CN (Cognitively Normal)**  \n**Confidence:** **Medium** (due to structural atrophy without cognitive or biomarker abnormalities)  \n\n*Note: The hippocampal and entorhinal atrophy are concerning for early neurodegeneration, but without cognitive impairment or biomarker evidence of Alzheimer’s pathology, this remains classified as CN. Follow-up monitoring is recommended.*",
  "timestamp": "2025-07-26T12:17:55.262827"
}